Stockreport

Kamada Announces Additional Interim Results from Phase 2 Proof of Concept Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection

Kamada Ltd. - Ordinary Shares  (KMDA) 
Last kamada ltd. - ordinary shares earnings: 2/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: kamada.com/investors.php
PDF Kamada’s IV-AAT demonstrated a trend towards improvements in multiple clinical outcomes, including days on mechanical ventilation post-transplant, pulmonary function at [Read more]